Background: Allergen immunotherapy has demonstrated usefulness in the management of allergic diseases such as asthma, allergic rhinitis and conjunctivitis. However, little is known about its effectiveness in vernal keratoconjunctivitis (VKC), a disease mediated by IgE and lymphocytes, that can cause loss of visual acuity in a permanent way.
Objective: To describe safety and effectiveness of allergen immunotherapy in a group of patients with VKC.